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Purpose: To determine the correlation between the volume of bone 
metastasis as assessed with diffusion-weighted (DW) 
imaging and established prognostic factors in metastatic 
castration-resistant prostate cancer (mCRPC) and the as-
sociation with overall survival (OS).
Materials and 
Methods:
This retrospective study was approved by the institutional 
review board; informed consent was obtained from all 
patients. The authors analyzed whole-body DW images 
obtained between June 2010 and February 2013 in 53 pa-
tients with mCRPC at the time of starting a new line of 
anticancer therapy. Bone metastases were identified and 
delineated on whole-body DW images in 43 eligible pa-
tients. Total tumor diffusion volume (tDV) was correlated 
with the bone scan index (BSI) and other prognostic fac-
tors by using the Pearson correlation coefficient (r). Sur-
vival analysis was performed with Kaplan-Meier analysis 
and Cox regression.
Results: The median tDV was 503.1 mL (range, 5.6–2242 mL), 
and the median OS was 12.9 months (95% confidence 
interval [CI]: 8.7, 16.1 months). There was a significant 
correlation between tDV and established prognostic fac-
tors, including hemoglobin level (r = 20.521, P , .001), 
prostate-specific antigen level (r = 0.556, P , .001), lac-
tate dehydrogenase level (r = 0.534, P , .001), alkaline 
phosphatase level (r = 0.572, P , .001), circulating tumor 
cell count (r = 0.613, P = .004), and BSI (r = 0.565, P = 
.001). A higher tDV also showed a significant association 
with poorer OS (hazard ratio, 1.74; 95% CI: 1.02, 2.96; 
P = .035).
Conclusion: Metastatic bone disease from mCRPC can be evaluated 
and quantified with whole-body DW imaging. Whole-body 
DW imaging–generated tDV showed correlation with es-
tablished prognostic biomarkers and is associated with 
OS in mCRPC.
q RSNA, 2016
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MR imaging, including DW imaging, 
between June 2010 and February 2013 
before starting a new line of antican-
cer therapy. Patients were included in 
the study if (a) whole-body MR imaging 
was performed within 4 weeks of start-
ing a new line of anticancer therapy, (b) 
bone metastases were identified on the 
basis of a review of images from com-
bined imaging modalities (MR imaging, 
CT [in all cases], and bone scintigraphy 
[when available]), (c) whole-body MR 
imaging was performed with a 1.5-T 
unit (according to the technical param-
eters described below), and (d) at least 
1 year of clinical follow-up data were 
available (or the patient died during 
the follow-up period). Patients were ex-
cluded if assessment with MR imaging 
was suboptimal owing to artifacts or in-
complete studies. Of 54 cases reviewed, 
43 were eligible for our study (all men; 
mean age, 69 years; age range, 41–80 
years). The mean time between MR 
imaging and the start of treatment was 
2.2 weeks. One case was not included 
positron emission tomography (PET)/
computed tomography (CT) (8,9). 
Moreover, functional MR imaging com-
plements anatomic sequences that as-
sess some biologic characteristics of 
the tumor. Diffusion-weighted (DW) 
imaging is a functional MR imaging tech-
nique that provides quantitative mea-
surement of the random displacement 
of water molecules (10). Previous stud-
ies have established the high sensitivity 
of DW imaging in the identification of 
bone metastases (11,12). DW imaging 
also allows easy delineation of areas of 
signal abnormality with semiautomated 
segmentation software; this provides the 
opportunity to more accurately deter-
mine the true extent of bone metastases. 
In addition, the apparent diffusion coef-
ficient (ADC) shows correlation with cell 
density in different tumor types, includ-
ing prostate cancer (13–17).
As part of a broader effort to clini-
cally qualify whole-body MR imaging of 
bone metastases for mCRPC, our study 
was conducted to determine the correla-
tion between volume of bone metastasis 
as assessed with DW imaging and es-
tablished prognostic factors in mCRPC 
and the association of volume of bone 
metastases with overall survival (OS).
Materials and Methods
This retrospective study was approved 
by the institutional review board. Ver-
bal informed consent was obtained for 
the acquisition of the MR images, and 
written informed consent was obtained 
for the acquisition of biologic samples 
from all patients.
Patient Population
Fifty-four male patients with mCRPC 
who were receiving treatment at a sin-
gle institution underwent whole-body 
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Advances in Knowledge
 n Semiautomated whole-body diffu-
sion-weighted (DW) imaging 
signal abnormality delineation is 
feasible, enabling the assessment 
of the total volume of bone 
metastasis in patients with meta-
static castration-resistant pros-
tate cancer (mCRPC).
 n Assessment of total volume of 
bone metastasies with whole-
body DW imaging informs on the 
overall survival of patients with 
mCRPC.
 n In our data set, the volume of 
bone metastases assessed with 
whole-body DW imaging showed 
correlation with established 
prognostic biomarkers for 
patients with advanced mCRPC, 
including circulating tumor cell 
count.
Implication for Patient Care
 n Assessment of the volume of 
bone metastases with whole-
body DW imaging in patients 
with mCRPC may help individu-
alize patient risk stratification 
and, therefore, treatment 
selection.
Prostate cancer is the second most common cancer and the fifth lead-ing cause of cancer death among 
men worldwide (1). Prostate cancer 
metastasizes primarily to the bone; skel-
etal dissemination occurs in up to 84% 
of patients (2), causing higher mor-
bidity and mortality in this population 
(3–5). Despite notable advances in the 
management of metastatic castration-
resistant prostate carcinoma (mCRPC) 
with new drugs, including abiraterone 
acetate and enzalutamide, which have 
been approved in the past 5 years (6,7), 
mCRPC remains ultimately a fatal con-
dition. Current bone imaging is inade-
quate, relying largely on bone scintig-
raphy with technetium 99m, an isotope 
taken up primarily by osteoblasts that is 
unable to accurately depict and quantify 
the true extent of metastatic disease to 
bone. The development of quantitative 
imaging biomarkers that can accurately 
evaluate the burden of bone metastases 
may help individualize patient risk strati-
fication and treatment selection and may 
ultimately be useful for evaluating the re-
sponse to treatment.
The accuracy of magnetic reso-
nance (MR) imaging in the detection of 
bone metastases is higher than that of 
bone scintigraphy and, possibly, choline 
Radiology: Volume 280: Number 1—July 2016 n radiology.rsna.org 153
MUSCULOSKELETAL IMAGING: Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted MR Imaging Perez-Lopez et al
high signal intensity on DW images ob-
tained with a b value of 900 sec/mm2 
and low signal intensity on T1-weight-
ed images, in keeping with metastatic 
bone disease, observed between C4 and 
midthighs were delineated. The skull 
vault and base were excluded owing to 
frequent artifacts, poor visualization of 
Geneva, Switzerland). The T1-weighted 
and DW images (b value = 50 and 900 
sec/mm2 and ADC maps) were evaluated 
to assess the presence of metastatic bone 
disease. Regions of interest including all 
areas of signal intensity abnormality on 
DW images obtained with a b value of 
900 sec/mm2, which corresponded to 
because whole-body MR imaging was 
not performed within 4 weeks of start-
ing a new line of treatment, six cases 
were excluded because there was no 
radiologic evidence of bone metasta-
ses, and four cases were excluded be-
cause of the presence of artifacts (eg, 
susceptibility artifacts) and/or incom-
plete studies (Fig 1).
Clinical Data Collection
Data were collected into an anony-
mized database. Patient characteris-
tics included age, previous anticancer 
treatments, Eastern Cooperative On-
cology Group performance status (18), 
and laboratory results (hemoglobin, 
prostate-specific antigen, lactate de-
hydrogenase, alkaline phosphate, and 
albumin levels) at the time of MR imag-
ing. Circulating tumor cell (CTC) count 
(19) and bone scan index (BSI) were 
included only if obtained within 12 
weeks of MR imaging (mean time from 
CTC count to MR imaging, 3.6 weeks; 
mean time from BSI to MR imaging, 
3.0 weeks). Follow-up data collected 
from electronic patient records in-
cluded survival status and OS (defined 
as time from MR imaging to death by 
any cause). For noncensored patients, 
follow-up data included the length of 
clinical follow-up.
Whole-Body MR Imaging Parameters
MR imaging was performed with pa-
tients in the supine position by using 
a 1.5-T unit (Avanto; Siemens Health-
care, Erlangen, Germany) with surface 
and body coils. Axial images were ac-
quired by using free-breathing single-
shot twice-refocused echo-planar DW 
imaging from vertex to midthighs, se-
quentially across four imaging stations, 
with each consisting of 50 sections. In 
addition to whole-body DW imaging, 
anatomic imaging was also performed 
by using a breath-hold axial T1-weight-
ed sequence. The imaging parameters 
used to perform whole-body MR imag-
ing are summarized in Table 1.
Image Analysis
Images were processed and analyzed 
with open-access imaging assistant soft-
ware (OsiriX v5.6; OsiriX Foundation, 
Figure 1
Figure 1: Flowchart of study selection process. WB = whole body.
Table 1
Imaging Parameters for Whole-Body DW Imaging
Parameter T1-weighted Imaging DW Imaging 
Type of pulse sequence Spoiled gradient echo (FLASH) Single-shot twice-refocused  
echo-planar imaging
Respiration Breath hold Free breathing
Type of acquisition 2D 2D
Field of view (mm) 380–420 380–420
Repetition time (msec) 380 14 000
Echo time (msec) 5 68
Inversion time (msec) NA 180
Flip angle (degrees) 70 90
Fat suppression NA STIR
Receiver bandwidth (Hz/pixel) 331 1800
No. of signals acquired 1 4
Section thickness (mm) 5 5
b value (sec/mm2) NA 50 and 900
No. of stations 4 (from vertex to midthighs),  
50 sections each
4 (from vertex to midthighs),  
50 sections each
Note.—A 1.5-T unit (Avanto, Siemens Healthcare) was used for the imaging platform. FLASH = fast low-angle shot, NA = not 
applicable, STIR = short inversion time inversion recovery, 2D = two-dimensional.
154 radiology.rsna.org n Radiology: Volume 280: Number 1—July 2016
MUSCULOSKELETAL IMAGING: Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted MR Imaging Perez-Lopez et al
after the first assessment and by a second 
radiologist (N.T., with 6 years of expe-
rience in whole-body DW imaging) who 
was blinded to the initial analysis with the 
purpose of assessing the intra- and inter-
observer reliability in tDV measurement.
CTC Count
CTCs were enumerated after isolation 
from blood samples by using a tumor 
cell kit (Cellsearch system; Janssen Di-
agnostics, Raritan, NJ), as described in 
a previous article (21). Results are ex-
pressed as the number of CTCs per 7.5 
mL of blood.
histogram representations of the ADCs 
of tDV for each patient were generated 
by using software (Excel 2010; Microsoft, 
Redmond, Wash).
Parameters analyzed at whole-body 
DW imaging included the tDV (defined 
as the number of pixels multiplied by 
the pixel volume in each case, account-
ing for differences in the size of the field 
of view), mean, median, skewness, and 
kurtosis of the ADC histogram for each 
patient.
A randomly selected subset of 10 
cases was analyzed again by the primary 
radiologist (R.P.L.) at least 6 months 
disease, and lower incidence of metasta-
ses in these locations (20). A semiauto-
matic segmentation tool from the OsiriX 
software was used for delineating bone 
disease. The delineation of total tumor 
diffusion volume (tDV) was performed by 
a radiologist (R.P.L.) with 2 years of expe-
rience in whole-body DW imaging; man-
ual correction of the segmentation mask 
corresponding to the volume of interest 
was performed when necessary (Fig 2). 
Pixel size and number of pixels for all 
volumes of interest were recorded to 
calculate the tDV for each patient. The 
ADC of every pixel was recorded, and 
Figure 2
Figure 2: Images show metastatic bone disease segmentation steps in two-dimensional coronal views for illustrative purpose. Areas of signal 
abnormality corresponding to (a) high signal intensity on DW image (b = 900 mm/sec2) and (b) low signal intensity on T1-weighted image, in 
keeping with bone metastases observed between C4 and the midthigh, were delineated and applied to the ADC map (c) to obtain ADCs in areas 
of interest. The overlaid colored mask is a three-dimensional representation of the tumor volume accounting for the apparent mismatch.
Radiology: Volume 280: Number 1—July 2016 n radiology.rsna.org 155
MUSCULOSKELETAL IMAGING: Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted MR Imaging Perez-Lopez et al
were log-transformed to account for 
the lack of normal distribution. The 
intra- and interobserver reliability of 
tDV measurements were assessed by 
using the Lin concordance correla-
tion coefficient of absolute agreement 
and Bland-Altman analysis. Limits of 
agreement were defined as the mean 
difference 6 1.96 times the standard 
deviation of the differences. The co-
efficient of repeatability was calcu-
lated as 1.96 times the standard de-
viation of the differences between 
the two measurements. Software 
(SPSS, version 20; IBM, Armonk, NY) 
was used for statistical analyses.
Results
Forty-three patients were eligible and 
included in the analysis. Twenty of the 
43 patients (46.5%) had metastatic 
disease limited to bone, 17 (39.5%) 
had bone and nodal disease, and six 
(14%) had visceral disease in addition 
to bone metastases.
Patients in our dataset had received 
a median of three (range, 0–7) lines 
of treatment for mCRPC at the time 
of MR imaging, including four patients 
(9.3%) who were treatment-naïve for 
mCRPC in whom MR imaging was per-
formed within 4 weeks before their 
first systemic treatment for mCRPC. 
Twenty-eight of the 43 patients (65.1%) 
had undergone previous treatment 
with at least abiraterone acetate and/
or enzalutamide and 29 (67.4%) were 
previously treated with taxane-based 
chemotherapy.
Thirty of the 43 patients (69.8%) 
died during the follow-up period, with 
13 patients (30.2%) alive at the time 
of data analysis. The median OS of the 
overall population was 12.9 months 
(95% CI: 8.7, 16.1 months), with a 
median follow-up of 11.1 months (in-
terquartile range [IQR]: 7.4–15.7 
months). Patient and tumor character-
istics, including treatment received be-
fore inclusion in our study, are summa-
rized in Table 2.
The median tDV was 503.1 mL 
(range, 5.6–2242 mL), with a median 
global ADC for the regions of interest 
the association of the variables with 
OS. The comparison between the dis-
criminative ability of MR imaging and 
bone scintigraphy in the prediction of 
OS was performed by assessing the 
status of each patient (dead vs alive) 
at several time points (9, 12, and 15 
months) and determining the area un-
der the receiver operating character-
istic curve (concordance index, or C-
index). Comparison between receiver 
operating characteristic curves was 
performed with the method estab-
lished by DeLong et al (23). The 95% 
confidence interval (CI) of the median 
ADC of the entire population was cal-
culated by means of bootstrapping. 
tDV, BSI, prostate-specific antigen 
level, CTC count, alkaline phosphate 
level, and lactate dehydrogenase level 
BSI Calculation
For those patients who underwent 
bone scintigraphy within 12 weeks of 
MR imaging and for whom Digital Im-
aging and Communication in Medicine 
images were available, the BSI was 
calculated by using an automated BSI 
scoring software system (Exini Diag-
nostics, Lund, Sweden) (22).
Statistical Analysis
The Pearson correlation coefficient (r) 
was determined to establish the cor-
relation between variables. Kaplan-
Meier analysis was used to study the 
OS of the population. Patients who 
were alive at the time of last follow-up 
were censored. Cox proportional haz-
ards models were used to determine 
Table 2
Baseline Characteristics and Previous Treatments of the Overall Population Included 
in the Final Analysis
Parameter Value* 
Baseline clinical  characteristics (n = 43)†
 Hemoglobin level (g/dL) 43 [11] (10–13)
 Prostate-specific antigen level (ng/mL) 43 [222] (69–1486)
 Alkaline phosphatase level (IU/L) 43 [140] (88–586)
 Lactate dehydrogenase level (IU/L) 43 [183] (151–247)
 Albumin level (g/dL) 43 [37] (32–39)
 BSI 32 [7.9] (2–11.5)
 CTC count (cells per 7.5 mL of blood) 21 [35] (7–148)
Prior treatments‡
 Docetaxel 29 (67.4)
 Cabazitaxel 10 (23.3)
 Abiraterone acetate 27 (62.8)
 Enzalutamide 7 (16.3)
 Radium-223 1 (2.3)
 Bisphosphonates 6 (14)
 Palliative radiation therapy to bone 22 (51.2)
Sites of metastatic disease‡
 Bone only 20 (46.5)
 Bone and nodal 17 (39.5)
 Bone and viscera 6 (14)
Metastatic bone disease characteristics
 Median tDV (mL)§ 503.1 (5.6–2242)
 Median ADC (x1026 mm2/sec)|| 813 (780, 906)
Median OS (mo)|| 12.9 (8.7, 16.1)
* Unless otherwise specified, data are numbers of patients.
† Numbers in brackets are medians. Numbers in paren theses are the IQR.
‡ Numbers in parentheses are percentages.
§ Numbers in parentheses are the range.
|| Numbers in parentheses are 95% CIs.
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0.97; 95% CI: 0.89, 1.06; P = .532) did 
not show a significant association with 
OS in our population.
Comparison of the Predictive Ability of 
Whole-Body DW Imaging and BSI
Among the 43 patients, 32 (74.4%) had 
BSI data available for analysis from bone 
scans obtained within the prespecified 
time ranges. Seven of the 43 patients 
(16.3%) underwent bone scintigraphy 
more than 12 weeks apart from MR 
imaging and were therefore excluded 
from this subanalysis. Two of the 43 pa-
tients (4.7%) did not have results from 
bone scintigraphy available, and two 
(4.7%) did not have Digital Imaging and 
Communications in Medicine images, 
which are necessary for BSI calcula-
tion, available. The median BSI was 7.9 
(IQR, 2–11.5). The tDV measured with 
whole-body DW imaging, as a continu-
ous variable, and the estimation relative 
to total skeletal mass by the BSI were 
highly correlated (r = 0.565, P = .001) 
(Fig 5). To further assess the prognostic 
performance of BSI and tDV, we eval-
uated mortality rates at 9, 12, and 15 
months (when approximately one-third, 
one-half, and two-thirds of patients had 
died). Receiver operating characteristic 
Next, we explored the correlation be-
tween tDV and CTC count. Baseline CTC 
counts were available for 21 of the 43 pa-
tients (48.8%). The median CTC count 
was 35 cells per 7.5 mL (IQR: 7–148 cells 
per 7.5 mL). CTC count showed signifi-
cant correlation with tDV (r = 0.613, P = 
.004), which is consistent with published 
evidence that high CTC count informs on 
worse prognosis in mCRPC (24) (Fig 5).
Association of tDV with OS
We hypothesized that the burden of 
bone disease would associate with OS 
in patients with mCRPC; tDV, as a con-
tinuous variable, showed a statistically 
significant association with OS, with 
patients with a higher tDV having an 
increased risk of death (hazard ratio: 
1.74; 95% CI: 1.02, 2.96; P = .035).
Association of Other Parameters Derived 
from Whole-Body DW Imaging with OS
Histogram parameters that describe 
the distribution of the global ADCs of 
bone metastases, such as mean (haz-
ard ratio: 1; 95% CI: 0.998, 1.001; P = 
.876), median (hazard ratio: 1; 95% CI: 
0.998, 1.002; P = .928), skewness (haz-
ard ratio: 0.92; 95% CI: 0.563, 1.504; 
P = .740), or kurtosis (hazard ratio: 
for each individual of 813 3 1026 mm2/
sec (95% CI: 780, 906 3 1026 mm2/
sec), median skewness of 1.5 (IQR: 
0.9–1.9), and median kurtosis of 3.5 
(IQR: 1.4–7). Histograms of the global 
ADCs for each patient and the whole 
population are shown in Figure 3. 
Two patients had bimodal histograms, 
with a high density of ADCs within 
500–1500 3 1026 mm2/sec and a small-
er peak within 2000–3000 3 1026 mm2/
sec. Both cases corresponded to pa-
tients who received focal palliative ra-
diation therapy to the pelvis during the 
6 months before MR imaging (Fig 4).
Correlation of tDV with Prognostic Factors
We investigated the correlation be-
tween tDV and known established 
prognostic factors, with special interest 
in those associated with bone disease 
(eg, hemoglobin and alkaline phosphate 
levels). Overall, tDV showed a signifi-
cant correlation with all of the stud-
ied established prognostic factors for 
mCRPC (hemoglobin level: r = 20.521, 
P , .001; prostate-specific antigen 
level: r = 0.556, P , .001; lactate de-
hydrogenase level: r = 0.534, P , .001; 
and alkaline phosphate level: r = 0.572, 
P , .001) (Table 3).
Figure 3
Figure 3: Left, histogram representation of ADCs for every patient included in analysis (n = 43). Right, volume density plot, where the y-axis represents the volume 
density per unit ADC. The area under the curve thus represents the total volume of disease in the patient population.
Radiology: Volume 280: Number 1—July 2016 n radiology.rsna.org 157
MUSCULOSKELETAL IMAGING: Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted MR Imaging Perez-Lopez et al
Figure 4
Figure 4: Images in 71-year-old man with mCRPC who underwent whole-body 
DW imaging in October 2012. He had received radiation therapy to right hemi-
pelvis in June 2012. (a) Axial whole-body DW image (b = 900 mm/sec2),  
(b) ADC map, and (c) histogram representation of ADCs show bimodal distribution 
with areas of high signal intensity on DW image and low ADC (arrowhead), in 
keeping with active and/or cellular disease, and areas of high signal intensity 
on DW image and high ADC (arrow) that represent treated and/or less-cellular 
disease.
curve analysis was performed to de-
termine the C-statistic (area under the 
receiver operating characteristic curve) 
with each of both imaging biomarkers 
at the specified time points. Although 
the area under the receiver operating 
characteristic curve for tDV was con-
sistently superior to that for BSI for 
9-month (0.745 vs 0.613, respectively; 
P = .141), 12-month (0.686 vs 0.627; 
P = .533), and 15-month (0.704 vs 
0.607; P = .345) mortality rates (Fig E1 
[online]), these differences were not sta-
tistically significant.
Intra- and Interobserver Reliability of tDV 
Measurement
The intraclass correlation coefficients 
were 0.986 (95% CI: 0.945, 0.996) and 
0.949 (95% CI: 0.857, 0.981) for intra- 
and interobserver comparison, respec-
tively. The Bland-Altman–calculated 
intraobserver coefficient of repeatabil-
ity was 0.302 L, and the interobserver 
coefficient of repeatability was 0.500 L. 
All values in the intra- and interob-
server Bland-Altman analysis are within 
the 95% limits of agreement.
Discussion
Bone involvement in patients with ad-
vanced prostate cancer is extremely 
common, resulting in higher morbidity 
and mortality in patients with mCRPC. 
When we consider the limitations of CT 
and bone scintigraphy in the accurate 
assessment of the extent of bone me-
tastases, it is imperative to develop new 
imaging biomarkers and pursue their 
analytical and clinical quantification, 
with the aim of providing new tools for 
guiding radiologists and clinicians in 
therapeutic decisions.
Our study shows an association 
between whole-body DW imaging 
parameters, OS, and prognostic fac-
tors in mCRPC, which was previously 
Table 3
Correlation of tDV and Other 
Prognostic Factors
Prognostic Factor
Correlation  
Coefficient* P Value
Hemoglobin level 20.521 ,.001
Prostate-specific  
antigen level
0.556 ,.001
Lactate dehydrogenase  
level
0.534 ,.001
Alkaline phosphatase  
level
0.572 ,.001
Albumin level 20.332 .030
CTC count 0.613 .004
Note.—The tDV, prostate-specific antigen level, lactate 
dehydrogenase level, alkaline phosphate level, and CTC 
count were log-transformed.
* Pearson correlation coefficient.
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differences did not reach statistical 
significance.
We acknowledge the potential lim-
itations of our study. First, the retro-
spective observational nature of our 
work, the variability in the number 
and type of treatments administered 
in the time between MR imaging and 
the start of therapy, and the presence 
of nodal and visceral disease in some 
of our patients are limitations. Second, 
because of the limited sample size of 
our pilot study, it is important to note 
that we did not control for clinical fac-
tors in the evaluation of the association 
between tDV and OS. A larger popula-
tion would be needed for future valida-
tion of these data, allowing for multi-
variate analysis—ideally in the setting 
of prospective studies. Third, there is 
a risk of underestimating the disease 
because the presented data included 
skeletal segmentation from the cervi-
cal spine to midthighs only. However, 
taking into account that the vast ma-
jority of bone metastases occur within 
the spine and pelvis (20), it is unlikely 
that this had a major effect on the as-
sessment of the total burden of meta-
static bone disease. Finally, it should 
be noted that delineation of the volume 
of interest is dependent on the quality 
of the acquired DW imaging data, the 
of disease with different cellular den-
sity distributions (27).
Parameters that help describe the 
distribution of the global ADCs of bone 
metastases, such as mean, median, 
skewness, or kurtosis, were not associ-
ated with OS in our population.
In the past few years it has been 
shown that indirect measurements of 
the burden of bone metastases, mea-
sured either as proportion of skele-
tal mass with BSI or the number of 
lesions visible at CT and PET/CT, 
provide prognostic information in 
prostate cancer (28,29). These exam-
inations, however, only largely reflect 
bone turnover as a response to either 
benign or malignant processes. MR 
imaging has been previously shown to 
have higher sensitivity and specificity 
than bone scintigraphy and CT in the 
detection of bone metastases (12). In 
our data set, the receiver operating 
characteristic curves with bone scin-
tigraphy were consistently inferior to 
those with whole-body DW imaging 
in the prediction of mortality, which 
suggests that the performance of DW 
imaging is superior. However, consid-
ering the limited population included 
in our study, formal comparisons 
in larger cohorts will be necessary 
to confirm this finding because the 
established in the literature. Notably, 
the volume of bone metastasis quan-
tified with whole-body DW imaging 
correlates with prognostic biomarkers 
routinely implemented into standard 
physician’s practice, such as hemo-
globin level, prostate-specific antigen 
level, and the bone turnover marker 
alkaline phosphate level. Interestingly, 
we also detected a correlation with 
CTC count, an established prognostic 
biomarker in mCRPC, although these 
findings must be corroborated in larger 
populations.
Histogram representation of the 
ADCs of the burden of metastatic 
bone disease may also provide a use-
ful representation of tissue cellularity. 
The median ADC for our population 
was 813 3 1026 mm2/sec; this value is 
lower than the median ADC reported 
in previous studies in other tumor 
types, including multiple myeloma 
(25), a disease with predominately 
lytic disease. In this mCRPC popula-
tion, conversely, metastases were 
mainly sclerotic (26). Studies in which 
DW imaging is used as a biomarker in 
cancer medicine, therefore, must ac-
count for such differences in disease 
biology among tumor types. Further-
more, bimodal histograms reflect the 
coexistence of two different patterns 
Figure 5
Figure 5: Scatterplots show relationship between tDV and CTC count and between tDV and BSI.
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